Silver Book Fact

New Medicines in Development for Parkinson’s Disease in 2018

Fact image

America's Biopharmaceutical Companies. Medicines in Development for Neurological Disorders: 2018 Report. Washington, D.C.: PhRMA; 2018. https://www.phrma.org/report/medicines-in-development-for-neurological-disorders-2018-report. Accessed June 11, 2019

Reference

Title
Medicines in Development for Neurological Disorders: 2018 Report
Publication
PhRMA
Publisher
PhRMA
Publication Date
2018
Authors
America's Biopharmaceutical Companies
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years were introduced in 2015, by 2050 the total reduction in cost of care for people…  
  • Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 total cost of care (for all payers) for all people…  
  • In one study, deep-brain stimulation for Parkinson’s patients significantly reduced their required dosages of antiparkinsonian medications, consequently decreasing their medication costs by 32% 1 year after surgery, and 39% 2…  
  • The U.S. Food and Drug Administration has approved five drugs that temporarily improve Alzheimer’s disease symptoms.